Jazz Pharmaceuticals to Buy GW Pharmaceuticals for $7.2 Billion

February 8, 2021

Jazz Pharmaceuticals is set to acquire GW Pharmaceuticals, a UK drugmaker known for its cannabidiol (CBD) products Epidiolex (cannabidiol) and Sativex (nabiximols), for a whopping $7.2 billion.

Sativex, a cannabis extract administered orally as a spray, received UK approval in 2010 for treatment of multiple sclerosis symptoms. The product is currently going through phase 3 trials to support FDA approval for treating spasticity associated with multiple sclerosis and spinal cord injury.

The acquisition also includes other cannabinoid product hopefuls in trials for autism and schizophrenia.

View today's stories